(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged #FutureFresenius, Biopharma platform, Bomyntra, cancer metastasis to bone, Conexxence, denosumab biosimilar, Europe, European Commission approval, Fresenius, Fresenius Kabi, Fresenius Kabi Deutschland GmbH, giant cell tumor of bone, high-quality biosimilars, osteoporosis, postmenopausal women, registered trademarks, skeletal complications, treatment-related bone loss
(IN BRIEF) Researchers from the University of Copenhagen have created “super stem cells” by altering the cells’ diet, enhancing their ability to differentiate into various cell types such as liver, skin, and nerve cells. This development has significant implications for … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged cellular differentiation, Diabetes, embryonic development, Fertility Treatment, heart failure, IVF, Joshua Brickman, liver cirrhosis, metabolic intervention, Novo Nordisk Foundation Center for Stem Cell Medicine, osteoporosis, Parkinson's disease, Regenerative medicine, RENEW, Robert Bone, Stem cells, super stem cells, University of Copenhagen, yolk sac
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?